ClinicalTrials.gov
public full text
Public Domain
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
This proposal translates a hypothesis driven basic research into clinical setting to determine the potential of using autologous CD133+ cells to reverse fibrosis and improve clinical outcome for patients with end stage cirrhosis. This has significant impact on the management of cirrhosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An integrated proteogenomic investigation of the human liver uncovers molecular drivers of steatotic liver disease#341966
- Assessment Of Lipid Profile In Cirrhotic Patients#800950
- To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase#863070
- A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.#1463173
- Liver Transplantation With Tregs at UCSF#811549
Record · ID 1465592
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive